Immunosuppression in Renal Cancer: Differential Expression of Signal Transduction Molecules in Tumor-Infiltrating, Near-Tumor Tissue, and Peripheral Blood Lymphocytes
- 1 January 2004
- journal article
- research article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 22 (6) , 871-877
Abstract
Alterations in the expression of signal activation molecules, such as the T-cell receptor (TCR) ζ and ε chains and p56lck tyrosine kinase, are described in tumor-infiltrating lymphocytes (TIL). The aim of this study was to ascertain if such molecules were present in near-tumor-tissue lmphocytes (NTTL) and peripheral blood lymphocytes (PBL), as well as TIL, of renal cell carcinoma patients, to verify whether this tumor induces immunosuppression only locally or affects distant lymphocytes as well. Tissue from the tumor and from healthy nearby sites, as well as blood samples, were obtained from 27 consecutive patients who had undergone radical nephrectomy for renal cell carcinoma. Phenotype analysis and immunohistochemical staining of the TCR ζ and ε chains and p56lck were performed with standard techniques on TIL, NTTL, and PBL, and values were compared for each patient. Low expression of the TCR ζ chain and an almost complete absence of TCR ε chain and p56lck expression was observed in TIL (median values: 10% for ζ chain and 0% for ε and p56lck). In NTTL, these signal transduction molecules were expressed by a higher percentage of cells (60%, 50%, and 60%, respectively; p = 0.000 vs. TIL), whereas PBL showed an almost normal expression of ζ and ε chains (80% and 90%, respectively; p = 0.000 vs. TIL). Conversely, p56lck was detected in a greater proportion of NTTL than PBL (50% vs. 10%; p = 0.001). The absence or the very low expression of signaling activation molecules in TIL compared with NTTL and PBL in renal cancer patients suggest that tumor-induced immunosuppression generally occurs or starts locally.Keywords
This publication has 14 references indexed in Scilit:
- Adjuvant Immunotherapy With Tumor Infiltrating Lymphocytes and Interleukin-2 in Patients With Resected Stage III and IV MelanomaJournal of Immunotherapy, 2003
- Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2British Journal of Cancer, 2003
- Signaling defects in T lymphocytes of patients with malignancyCancer Immunology, Immunotherapy, 1999
- Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapyCancer Immunology, Immunotherapy, 1999
- Interleukin-10–Treated Human Dendritic Cells Induce a Melanoma-Antigen–Specific Anergy in CD8+ T Cells Resulting in a Failure to Lyse Tumor CellsBlood, 1999
- The role of Fas/FasL in immunosuppression induced by human tumorsCancer Immunology, Immunotherapy, 1998
- Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patientsCancer Immunology, Immunotherapy, 1998
- Transfer of the Interleukin-2 Gene Into Human Cancer Cells Induces Specific Antitumor Recognition and Restores the Expression of CD3/T-Cell Receptor Associated Signal Transduction MoleculesBlood, 1997
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996
- Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapyImmunology Today, 1996